ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
17.2 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | ACADIA Pharmaceuticals Inc. |
Symbool | ACAD |
Munteenheid | USD |
Prijs | 17.2 |
Beurswaarde | 2,853,067,200 |
Dividendpercentage | 0% |
52-weken bereik | 14.15 - 32.59 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephen R. Davis J.D. |
Website | https://www.acadia-pharm.com |
An error occurred while fetching data.
Over ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)